{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:37:13Z","timestamp":1776778633381,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05684-1","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T01:02:54Z","timestamp":1709946174000},"page":"5881-5889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009\u20132020"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-9644","authenticated-orcid":false,"given":"Marina Xavier","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-7338","authenticated-orcid":false,"given":"Adriano Max Moreira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-7424","authenticated-orcid":false,"given":"Paula Lana de Miranda","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-393X","authenticated-orcid":false,"given":"J\u00e9ssica Soares","family":"Malta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-6096","authenticated-orcid":false,"given":"L\u00edvia Pena","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-3188","authenticated-orcid":false,"given":"Cristiane Aparecida","family":"Menezes de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"issue":"8","key":"5684_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107. https:\/\/doi.org\/10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"issue":"5","key":"5684_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"issue":"1","key":"5684_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, Hu Y, Huang H (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606. https:\/\/doi.org\/10.1186\/s12885-021-08280-y","journal-title":"BMC Cancer"},{"key":"5684_CR4","unstructured":"IHME (2015) Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington. https:\/\/www.healthdata.org\/. Accessed November 2023"},{"key":"5684_CR5","unstructured":"Brasil (2023) Minist\u00e9rio da Sa\u00fade. Diretrizes Diagn\u00f3sticas e Terap\u00eauticas do Mieloma M\u00faltiplo. https:\/\/www.gov.br\/conitec\/pt-br\/midias\/consultas\/relatorios\/2022\/20220526_ddt_mieloma_multiplo_cp.pdf. Accessed"},{"issue":"11","key":"5684_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.clml.2017.06.022","volume":"17","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, Gonz\u00e1lez-Calle V (2017) Smoldering multiple myeloma: who and when to treat. Clin Lymphoma Myeloma Leuk 17(11):716\u2013722. https:\/\/doi.org\/10.1016\/j.clml.2017.06.022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5684_CR7","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y (2023) CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol 14:1101495. https:\/\/doi.org\/10.3389\/fimmu.2023.1101495","journal-title":"Front Immunol"},{"issue":"3","key":"5684_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00277-019-03601-5","volume":"98","author":"A Sen\u00edn","year":"2019","unstructured":"Sen\u00edn A, Garc\u00eda-Pallarols F, Ben Azaiz R, Mart\u00ednez-Serra L, Montesdeoca S, Rom\u00e1n D, Ferraro M, P\u00e1rraga I, Besses C, Abella E (2019) Study of the frequency and reasons for discontinuation of different lines of treatment in patients with multiple myeloma. Ann Hematol 98(3):705\u2013711. https:\/\/doi.org\/10.1007\/s00277-019-03601-5","journal-title":"Ann Hematol"},{"issue":"2","key":"5684_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252\u2013264. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"issue":"2","key":"5684_CR10","first-page":"165","volume":"10","author":"A Maiolino","year":"2018","unstructured":"Maiolino A, Neto J, Leite L, Seguro F, Braga W, Zanella K, Sobrinho J, Oliveira R, Julian G, Tanaka P (2018) Unmet needs in multiple myeloma in Brazil from physicians\u2019 perspective \u2013 barriers in quality of life and disease management. J Bras Econ Sa\u00fade 10(2):165\u2013171","journal-title":"J Bras Econ Sa\u00fade"},{"issue":"3","key":"5684_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.soncn.2017.05.008","volume":"33","author":"P Bertolotti","year":"2017","unstructured":"Bertolotti P, Pierre A, Rome S, Faiman B (2017) Evidence-based guidelines for Preventing and Managing Side effects of multiple myeloma. Semin Oncol Nurs 33(3):332\u2013347. https:\/\/doi.org\/10.1016\/j.soncn.2017.05.008","journal-title":"Semin Oncol Nurs"},{"issue":"1","key":"5684_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175(1):66\u201376. https:\/\/doi.org\/10.1111\/bjh.14193","journal-title":"Br J Haematol"},{"key":"5684_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00025","volume":"5","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, Arrais C, Avenda\u00f1o Flores O, Barroso F, Basquiera AL, Cao C, Cugliari MS, Enrico A, Foggliatto LM, Galvez KM, Gomez D, Gomez A, de Iracema D, Farias D, Lopez L, Mantilla WA, Mart\u00ednez D, Mela MJ, Miguel CE, Ovilla R, Palmer L, Pavlovsky C, Ramos C, Remaggi G, Santucci R, Schusterschitz S, Sossa CL, Tuna-Aguilar E, Vela J, Santos T, de la Mora O, Machnicki G, Fernandez M, Barreyro P (2019) Epidemiology of hematologic malignancies in Real-World settings: findings from the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol 5:1\u201319. https:\/\/doi.org\/10.1200\/jgo.19.00025","journal-title":"J Glob Oncol"},{"issue":"7","key":"5684_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","volume":"126","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Richardson P, San Miguel JF (2015) Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 126(7):921\u2013922. https:\/\/doi.org\/10.1182\/blood-2015-05-647636","journal-title":"Blood"},{"issue":"8","key":"5684_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"5684_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blad\u00e9 J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22(8):1485\u20131493. https:\/\/doi.org\/10.1038\/leu.2008.131","journal-title":"Leukemia"},{"key":"5684_CR17","unstructured":"National Cancer Institute. Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017) https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed January 2023"},{"issue":"1","key":"5684_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C (2005) Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 75(1):27\u201333. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00446.x","journal-title":"Eur J Haematol"},{"issue":"7","key":"5684_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1592\/phco.2005.25.7.963","volume":"25","author":"SO Butler","year":"2005","unstructured":"Butler SO, Btaiche IF, Alaniz C (2005) Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy 25(7):963\u2013976. https:\/\/doi.org\/10.1592\/phco.2005.25.7.963","journal-title":"Pharmacotherapy"},{"key":"5684_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/1574886318666230817162424","author":"PLM Drummond","year":"2023","unstructured":"Drummond PLM, Santos RMM, Silveira LP, Malta JS, Reis AMM, Costa NL, Silva ROP, Fagundes EM, de Menezes CA (2023) Chemotherapy-Induced Peripheral Neuropathy impacts Quality of Life and activities of Daily Living of Brazilian multiple myeloma patients. Curr Drug Saf. https:\/\/doi.org\/10.2174\/1574886318666230817162424","journal-title":"Curr Drug Saf"},{"key":"5684_CR21","doi-asserted-by":"publisher","unstructured":"Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, Ocheni S, Theurich S, Kuhr K, Scheckel B, Adams A, Skoetz N (2019) Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2019 11. https:\/\/doi.org\/10.1002\/14651858.cd013487","DOI":"10.1002\/14651858.cd013487"},{"issue":"16","key":"5684_CR22","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.12968\/bjon.2016.25.S18","volume":"25","author":"M Dowling","year":"2016","unstructured":"Dowling M, Kelly M, Meenaghan T (2016) Multiple myeloma: managing a complex blood cancer. Br J Nurs 25(16):S18\u201328. https:\/\/doi.org\/10.12968\/bjon.2016.25.S18","journal-title":"Br J Nurs"},{"key":"5684_CR23","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma, Washington PA, NCCN (2014) ; https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma-portuguese.pdf. Accessed October 2023"},{"issue":"8","key":"5684_CR24","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1200\/op.21.00883","volume":"18","author":"A McBride","year":"2022","unstructured":"McBride A, Hudson-DiSalle S, Pilz J, Hamm M, Boring B, Buie LW, DeRemer DL (2022) National Survey on the Effect of Oncology drug shortages in clinical practice: a Hematology Oncology Pharmacy Association Survey. JCO Oncol Pract 18(8):e1289\u2013e1296. https:\/\/doi.org\/10.1200\/op.21.00883","journal-title":"JCO Oncol Pract"},{"key":"5684_CR25","doi-asserted-by":"crossref","unstructured":"Rosa MB, Reis AMM, Perini E (2016) Drug shortage: a public health problem. Cad Saude Publica 32","DOI":"10.1590\/0102-311X00086916"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05684-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:05:48Z","timestamp":1735866348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5684"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05684-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}